NCT01619839

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 296 (actual)
• Sponsor: Nektar Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe chronic pain - active as a mu agonist, but with inherent molecular properties designed to provide a unique clinical profile, including most notably, reduced CNS side effects and an attenuated attractiveness as a target of abuse.

Conditions

• Osteoarthritis of the Knee

Interventions

Type	Name	Description
DRUG	NKTR-181
DRUG	Placebo	Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-08-01
• Completion: 2013-09-01
• First posted: 2012-06-14
• Last updated: 2021-08-02
• Results posted: 2021-08-02

Locations

34 sites across 1 country: United States